Patient P-01452

Synthetic patientNBL-101 · Day 90 · 55–64 · M · baseline S02Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

61%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S02
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 64 GI symptom burden −29% vs expected — GI Support Protocol GI-04
Day 70 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Treatment adherence-7
Nutritional resilience-5
GI instability+2
Toxicity+2

What helped?

GI Support Protocol GI-04Day 55
Result: symptom burden −29%

LIFE OS recommendation

Dietary Support Protocol NP-02

54%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
- WearableSleep 5.9 h, below personal baseline
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
Autonomic recovery ↓45
- WearableResting HR 81 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 49

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.1 · butyrate capacity 23/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 44 ms
Sleep: 5.3 h
Steps: 4,623
Resting HR: 83 bpm

Daily log: GI score 53, nutritional resilience 39, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01349	47%	S14	GI-04	improved	38
P-01423	47%	S19	GI-04	improved	44
P-01547	47%	S13	GI-04	improved	50
P-01360	46%	S14	GI-04	improved	52
P-01494	46%	S14	GI-04	improved	42
P-01786	46%	S07	ME-01	improved	46
P-01433	45%	S14	GI-04	improved	48
P-01554	45%	S05	GI-04	improved	47
P-01539	44%	S14	GI-04	improved	43
P-01667	44%	S10	GI-04	improved	49
P-01488	43%	S12	GI-04	improved	50
P-01570	43%	S14	SC-12	improved	46